Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research Market

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research MarketAuthor of the article:TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Nox Peptides today announced the launch of two research-focused peptide products, GHK-Cu and the Wolverine Stack, expanding its product offering for Canadian laboratories, researchers and research organizations.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe product launch gives research-focused customers access to individual and combination peptide products through the Nox Peptides online catalog. The company says the new additions are intended to support laboratory and preclinical research applications and are supplied with research-use information and product documentation.This advertisement has not loaded yet, but your article continues below.GHK-Cu is a copper-binding peptide that has been the subject of scientific research for several decades. Researchers have investigated the compound in various laboratory settings, contributing to research examining peptide biology and cellular processes.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againAs part of the announcement, Nox Peptides has introduced GHK-Cu as a standalone research product for laboratory applications. The company states that the product is intended exclusively for research purposes and is not marketed as a medication or treatment for human use.Nox Peptides has also introduced the Wolverine Stack, a combination research product containing multiple peptides, including BPC-157 and TB-500. The company says the combination product is intended for laboratory research where investigators may be studying multiple peptide compounds within the same research framework.According to Nox Peptides, the newly introduced products are accompanied by information intended to help researchers identify research materials and review relevant product documentation. Researchers are encouraged to evaluate product specifications, batch information, certificates of analysis, storage requirements and other available documentation before using research materials.This advertisement has not loaded yet, but your article continues below.The company says the product launch reflects its continued focus on serving the Canadian research supply market with peptide materials intended for laboratory and preclinical research.Nox Peptides also emphasizes that researchers and organizations are responsible for ensuring that purchasing, storage, handling and use of research materials comply with applicable Canadian laws, institutional policies and laboratory protocols.With the launch of GHK-Cu and the Wolverine Stack, Nox Peptides is expanding its research-product catalog while maintaining a focus on research-use labeling, product identification and responsible handling of laboratory materials.Nox Peptides provides peptide products intended for laboratory and research purposes. Its product selection includes individual research peptides and combination products intended for qualified research applications.Products referenced in this announcement are intended for laboratory research purposes only. They are not intended for human or veterinary use, diagnosis, treatment, prevention or cure of any disease or medical condition. Nothing in this announcement should be interpreted as a medical claim or recommendation for human administration.Media InfoNox Peptidesinfo@noxpeptides.sthttps://noxpeptides.ca/This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.